Merck & Co., Inc. (MRK) 2025 10-K Earnings Analysis
Merck & Co., Inc.2025 Earnings Analysis
64/100
FY2024 → FY2025 Year-over-Year
vs prior annual reportIn FY2025, Merck & Co., Inc.'s net income grew 6.6% to $18.3B and revenue grew 1.3% to $65.0B, while free cash flow declined 31.7% to $12.4B and overall score dropped 12 to 64.
MRK's FY2025 10-K reveals a pharmaceutical giant with extraordinary Keytruda dependency: $65.0B revenue with 74.8% gross margin, $12.4B FCF, and Keytruda alone generating $31.7B (49% of total sales). Pricing power is strong in oncology where Keytruda holds first-mover advantages across 20+ approved indications. The moat is wide in immuno-oncology but faces an existential cliff as Keytruda's patent protection wanes — Winrevair ($1.4B) and the broader pipeline must deliver multi-billion dollar replacements. Gardasil's decline from $8.9B to $5.2B illustrates what patent cliffs look like.
Filing analysis
Merck & Co., Inc. 2025 10-K Analysis
This page reads Merck & Co., Inc.'s 2025 10-K annual report through the EarningsMoat framework: earnings quality, economic moat strength, capital allocation, and key risks. The current overall score is 64/100, or grade D.
MRK Earnings Quality
The earnings-quality module scores 80/100, with Gross Margin: 74.8%, CF/Net Income: 0.90x. The core question is whether reported profit is backed by operating cash flow and recurring business economics. See the earnings quality analysis guide.
MRK Economic Moat Analysis
The moat-strength module scores 72/100, with Keytruda Franchise: 85/100, Pipeline/Diversification: 65/100. The test is whether the advantage can protect returns after competitors react. Read the economic moat analysis guide.
MRK Free Cash Flow vs Net Income
CF/Net Income: 0.90x, Free Cash Flow: $12.4B is the fastest read on whether accounting earnings turn into cash. The capital-allocation module scores 72/100. For the diagnostic, start with cash flow vs net income.
MRK Key Risks from the Annual Report
The risk module scores 30/100, with Keytruda Patent Cliff: Critical, Pipeline Execution: High. The goal is to separate ordinary disclosure from risks that can change margins, cash flow, leverage, or the moat itself.
Is MRK a High Quality Earnings Stock?
Based on this 2025 filing, MRK needs a closer read before it qualifies as a high-quality earnings candidate: the overall grade is D, and the earnings-quality score is 80/100. This is a research screen, not investment advice.
Read the report first
Understand Merck & Co., Inc. first, then decide if it belongs on your watchlist
The MRK score, explanation, management facts, and filing sources are all here. When you want to follow more companies, review new-filing changes, or keep notes for the next review, keep more names in your watchlist.
Read the report first
Understand the company first. Keep up with every filing as your list grows.
A single report helps you judge one company. As your watchlist grows, review score, cash flow, moat, and risk changes together instead of repeating the same work.
Keep more names together
When your list grows, keep MRK with the rest of your names and review score, grade, and risk changes over time.
See how to track more namesAsk follow-up questions
Dig into cash conversion, moat evidence, capital allocation, and risk changes without rereading the full 10-K.
Ask a questionExport and revisit records
Save the MRK report as research notes you can revisit before the next filing.
Save research notesCore Dimension Scores
Evaluating competitive strength across earnings quality, moat strength, and risk sustainability
Overall Score Trend
Earnings Quality
Gross margin of 74.8% on $65.0B revenue is strong pharmaceutical-grade profitability, driven by Keytruda's premium oncology pricing and biologic manufacturing efficiency. The margin reflects a portfolio weighted toward high-value patent-protected drugs with limited generic/biosimilar competition.
Operating cash flow of $16.5B against net income of $18.3B yields a 0.90x conversion ratio — solid, with the gap reflecting timing of R&D spending, milestone payments, and working capital movements. Overall cash quality is strong.
Free cash flow of $12.4B ($16.5B OCF less $4.1B capex) represents a 19.0% FCF margin. The $4.1B capex funds manufacturing expansion for Keytruda and pipeline products. $12.4B in distributable cash covers MRK's ~$8B annual dividend with room for R&D and acquisitions.
Keytruda/Keytruda Qlex generated $31.7B in FY2025 — 48.7% of total sales and growing from $25.0B in FY2023. This extreme concentration means nearly half of MRK's revenue depends on a single drug franchise, creating binary risk around patent expiry and biosimilar competition.
Earnings quality scores 80/100 — strong pharmaceutical margins and cash generation dominated by a single blockbuster. The 74.8% gross margin, 0.90x CF/NI, and $12.4B FCF demonstrate high-quality earnings from a patent-protected oncology portfolio. However, the 48.7% concentration in Keytruda is the critical quality concern — this level of single-product dependency is extreme even by pharma standards.
Moat Strength
Keytruda is approved across 20+ cancer types including NSCLC, melanoma, urothelial cancer, HNSCC, and many more per the 10-K. The subcutaneous formulation (Keytruda Qlex) extends the franchise. Keytruda's breadth of indications creates deep physician familiarity and institutional adoption that would be extremely difficult for competitors to displace.
Beyond Keytruda, MRK has Winrevair ($1.4B in first full year), Gardasil ($5.2B), Januvia/Janumet ($2.5B), and Lynparza alliance ($1.5B). The Animal Health segment ($6.4B) provides non-pharma diversification. However, no single product comes close to replacing Keytruda's $31.7B — the replacement math requires multiple simultaneous successes.
Keytruda's core patents begin expiring in the late 2020s. The 10-K shows Gardasil declining from $8.9B (FY2023) to $5.2B (FY2025) — a 42% decline — demonstrating how quickly biosimilar/generic competition erodes even blockbuster franchises. Keytruda will face a similar trajectory once biosimilar pembrolizumab enters the market.
Moat strength scores 72/100 — a deep but time-limited moat built on Keytruda's immuno-oncology dominance. The franchise is extraordinarily strong today — $31.7B from 20+ indications — but the approaching patent cliff makes this a moat with an expiration date. The Gardasil decline ($8.9B to $5.2B in two years) is a live demonstration of what awaits Keytruda. The pipeline must deliver multiple blockbusters simultaneously to maintain MRK's earnings power.
Capital Allocation
MRK invests approximately $13B annually in R&D (~20% of revenue), one of the highest ratios in pharma. This is critical for building the pipeline needed to replace Keytruda revenue as patents expire. Key programs include Winrevair (pulmonary hypertension), Capvaxive (pneumococcal vaccine), and Welireg (oncology).
Total debt ratio of 61.6% with $46.8B long-term debt is moderately elevated, reflecting borrowing to fund acquisitions and pipeline development. Debt-to-FCF of ~3.8x is manageable but elevated for a company facing a major patent cliff within 5 years.
MRK's ~$8B annual dividend represents approximately 65% of $12.4B FCF — a somewhat elevated payout ratio for a company that needs to invest aggressively in pipeline development. The dividend is currently well-covered but could come under pressure post-Keytruda patent cliff.
Capital allocation scores 72/100 — heavy R&D investment is the right strategic priority but execution is uncertain. MRK is spending ~20% of revenue on R&D to build the post-Keytruda pipeline, which is the correct allocation decision. However, the ~65% dividend payout ratio limits reinvestment flexibility, and the 61.6% debt ratio constrains M&A firepower precisely when the company needs to acquire pipeline assets most aggressively.
Key Risks
Keytruda's $31.7B (49% of sales) faces patent expiry in the late 2020s. The 10-K's own data shows the precedent: Gardasil declined 42% from $8.9B to $5.2B in two years as competition intensified. Keytruda's patent cliff is the single largest binary risk in all of pharma — the loss of $31.7B in revenue would be catastrophic without adequate replacement.
Replacing $31.7B in Keytruda revenue requires multiple simultaneous pipeline successes. Winrevair ($1.4B first year) is promising but far from sufficient. The 10-K acknowledges 'significant costs and uncertainties in the pharmaceutical research and development process' and 'the timing and process of obtaining regulatory approvals.'
Medicare drug price negotiation under the IRA could directly target Keytruda, the highest-revenue drug in the U.S. Any government-mandated price reduction on a $31.7B franchise would have material earnings impact. International reference pricing amplifies this risk globally.
Key risks score 30/100 — the Keytruda patent cliff is the defining risk, creating a potential earnings collapse within 5 years without adequate pipeline replacement. MRK faces a mathematical challenge: $31.7B in Keytruda revenue must be replaced by a combination of pipeline products (Winrevair, Capvaxive, Welireg, others), none of which individually approaches Keytruda's scale. The Gardasil precedent ($8.9B to $5.2B) demonstrates how quickly even dominant franchises erode.
Management
Ask about this section
Ask one question here. Keep digging when the issue needs more work.
This analysis is for educational purposes only and does not constitute investment advice.